PRESSEPORTAL Presseportal Logo
Alle Storys
Keine Story von curasan AG mehr verpassen.

26.03.2007 – 11:04

curasan AG

curasan AG: Worldwide distribution rights for Epi-Guide®

Kleinostheim (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
curasan AG (WKN 549 453 8) has been
granted worldwide distribution rights by Kensey Nash Corporation, 
USA, for Epi-Guide®, their bioresorbable membrane. This is an 
extension to a cooperation established in 2001 which has, so far, 
comprised sales in Germany, several other European countries and - 
since 2005 - the United States.
"International distribution rights open up additional revenue 
potential and create synergies in the expansion of marketing 
activities by way of supra-regional opinion leaders and by offering 
our distributors an even more balanced, and thus more attractive, 
product range", says Chairman Hans Dieter Roessler.
Epi-Guide® is a uniquely structured bioresorbable synthetic membrane 
with many applications within guided tissue regeneration (GTR) and 
guided bone regeneration (GBR). Suggestions for improvement, made to 
the manufacturer by curasan, significantly contributed to the 
development of a new generation of membranes which is now available 
as an optimized product.
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an 
exchange-listed company, is a leading innovator within the growth 
market of bone and tissue regeneration. The company has developed a 
comprehensive product range centred around its synthetic bone 
regeneration material Cerasorb®, for use in soft and hard tissue. 
With the REVOIS® implant system, the company's sales is focusing more
prominently on the growth market of dental surgery/implantology. The 
majority of new products emerging from the substantial development 
pipeline are to be offered under licence within other medical fields.
Please visit curasan's corporate website at
end of announcement                               euro adhoc 26.03.2007 11:03:00

Further inquiry note:

Dr. Erwin Amashaufer, curasan AG, phone +49 6027 4686-465, email:
Andrea Weidner, curasan AG, phone +49 6027 4686-467, email:

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade